SARS-CoV-2, COVID-19VALOR-C19 UPMCNCT05667116
eVusheld Assessment reaL wORld Effectiveness at UPMC
An observational study of SARS-CoV-2, COVID-19, run by AstraZeneca at 1 site in United States.
Trial summary
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the… Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- SARS-CoV-2, COVID-19
- What is being tested?
- EVUSHELD
- How many people
- 4,232 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Jan 2023to 24 Jul 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All EVUSHELD EUA-eligible patient population in the UMPC health system.
Who may be able to join
- Receipt of EVUSHELD under the FDA EUA for EVUSHELD
- Eligibility for assess Evusheld use under the EUA. -
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations Receiving Care at UPMC in the United States
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the University of Pittsburgh Medical Center (UPMC) Health System.
Read the detailed description
This a Phase IV observational, secondary data study to assess the effectiveness of Evusheld in preventing COVID-19 infection and severe outcomes using the electronic medical records from the nationwide integrated health system.
The study is designed as an AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in UPMC health system
- Conditions
- SARS-CoV-2, COVID-19
- Being tested
- EVUSHELD
- Keywords
- EVUSHELD, AZD7442, SARS-CoV-2, COVID-19, Immunocompromise
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EVUSHELDDrug
EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
| Study group | Role | What they receive |
|---|---|---|
| EVUSHELD arm | 3,000 Individuals given EVUSHELD for pre-exposure prophylaxis Receives: Drug: EVUSHELD | |
| Concurrent Control arm | 3,000 individuals eligible for EVUSHELD pre-exposure prophylaxis but did not receive Evusheld |
What is being measured
The primary outcome is the main question the study is designed to answer.
COVID-19 hospitalisation
To assess the effectiveness of EVUSHELD as PrEP against COVID-19 hospitalisation
Measured: 6 months
All-cause mortality
To assess the effectiveness of EVUSHELD as PrEP against all-cause mortality
Measured: 6 months
Secondary outcomes (5)
SARS-CoV-2 infection
To assess the effectiveness of EVUSHELD as PrEP against documented SARS-CoV-2 infection
Measured: 6 & 12 months
Medically attended COVID-19
To assess the effectiveness of EVUSHELD as PrEP against medically attended COVID-19
Measured: 6 & 12 months
Medically attended acute COVID-19
To assess the effectiveness of EVUSHELD as PrEP against medically attended acute COVID-19
Measured: 6 & 12 months
COVID-19 hospitalisation
To assess the effectiveness of EVUSHELD as PrEP against COVID-19 hospitalisation
Measured: 12 months
COVID-19 intensive care unit (ICU) admission
To assess the effectiveness of EVUSHELD as PrEP against COVID-19 intensive care unit (ICU) admission
Measured: 6 & 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Dec 2022
- Study start9 Jan 2023
- Primary completion24 Jul 2023
- Study completion24 Jul 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SARS-CoV-2, COVID-19Studies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 4,232 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- University of Pittsburgh
- Responsible party
- Sponsor
- Investigators
- Donald M Yealy, MD, Principal investigator, University of Pittsburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05667116
- Sponsor's protocol ID
- D8850R00001
- Acronym
- VALOR-C19 UPMC
- Status last verified
- Nov 2024
- First submitted
- 19 Dec 2022
- Last updated
- 12 Nov 2024
- Results posted
- No
- FDA-regulated drug
- Yes
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 12 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Observational Study to Assess the Real-world Effectiveness of EVUSHELD™ (Tixagevimab/Cilgavimab) as Pre-exposure Prophylaxis Against COVID-19 Among EVUSHELD-eligible Populations Receiving Care at UPMC in the United States
- ClinicalTrials.gov ID
- NCT05667116
- Acronym / sponsor ID
- VALOR-C19 UPMC / D8850R00001
- Conditions
- SARS-CoV-2, COVID-19
- Keywords
- EVUSHELD, AZD7442, SARS-CoV-2, COVID-19, Immunocompromise
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 4,232 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Collaborators
- University of Pittsburgh
- Study start
- 9 Jan 2023 (actual)
- Primary completion
- 24 Jul 2023 (actual)
- Study completion
- 24 Jul 2023 (actual)
- First posted
- 28 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the University of Pittsburgh Medical Center (UPMC) Health System.
Detailed description
This a Phase IV observational, secondary data study to assess the effectiveness of Evusheld in preventing COVID-19 infection and severe outcomes using the electronic medical records from the nationwide integrated health system.
The study is designed as an AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in UPMC health system
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| EVUSHELD arm | – | Drug: EVUSHELD3,000 Individuals given EVUSHELD for pre-exposure prophylaxis |
| Concurrent Control arm | – | –3,000 individuals eligible for EVUSHELD pre-exposure prophylaxis but did not receive Evusheld |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All EVUSHELD EUA-eligible patient population in the UMPC health system.
Key inclusion criteria (2 listed)
- Receipt of EVUSHELD under the FDA EUA for EVUSHELD
- Eligibility for assess Evusheld use under the EUA. -
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EVUSHELDEVUSHELD (AZD 7442, Tixagévimab/Cilgavimab) | Drug | EVUSHELD arm |
Primary outcome
COVID-19 hospitalisation
Time frame: 6 months
To assess the effectiveness of EVUSHELD as PrEP against COVID-19 hospitalisation
All-cause mortality
Time frame: 6 months
To assess the effectiveness of EVUSHELD as PrEP against all-cause mortality
5 secondary outcomes
SARS-CoV-2 infection
Time frame: 6 & 12 months
Medically attended COVID-19
Time frame: 6 & 12 months
Medically attended acute COVID-19
Time frame: 6 & 12 months
COVID-19 hospitalisation
Time frame: 12 months
COVID-19 intensive care unit (ICU) admission
Time frame: 6 & 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Nov 2024.
- Redacted\_CSR Synopsis\_D8850R00001Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Related trials for SARS-CoV-2, COVID-19
RecruitingPhase 3
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
SARS-CoV-2
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingPhase 2
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
COVID 19, Influenza
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Donald M Yealy, MD principal investigator
University of Pittsburgh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of SARS-CoV-2, COVID-19, run by AstraZeneca at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
COVID-19 hospitalisation (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Nov 2024.